Aspirin tablets — Competitive Intelligence Brief

Aspirin tablets (Aspirin tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent. Area: Cardiovascular; Pain management; Inflammation.

marketed Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) Cardiovascular; Pain management; Inflammation Small molecule

Target snapshot

Aspirin tablets (Aspirin tablets) — PLx Pharma. Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to provide anti-inflammatory, analgesic, and antiplatelet effects.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aspirin tablets TARGET	Aspirin tablets	PLx Pharma	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Surgery with Naproxen	Surgery with Naproxen	Giovana Maria Weckwerth	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Diclofenac Sodium Topical Gel, 1%	Diclofenac Sodium Topical Gel, 1%	Amneal Pharmaceuticals, LLC	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
ibuprofen suppositories	ibuprofen suppositories	Soroka University Medical Center	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
ketorolac tromethamine 0.4%	ketorolac tromethamine 0.4%	Clinica Oftamologica Zona Sul	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
lysine acetylsalicylate	lysine acetylsalicylate	Azienda Ospedaliera San Giovanni Battista	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Ibuprofen Tablets	Ibuprofen Tablets	Overseas Pharmaceuticals, Ltd.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent class)

1. Assistance Publique - Hôpitaux de Paris · 3 drugs in this class
2. Basque Health Service · 2 drugs in this class
3. PLx Pharma · 2 drugs in this class
4. Biogen · 1 drug in this class
5. Eli Lilly and Company · 1 drug in this class
6. Harbin Medical University · 1 drug in this class
7. Janssen Scientific Affairs, LLC · 1 drug in this class
8. Azienda Ospedaliera San Giovanni Battista · 1 drug in this class
9. Royal College of Surgeons, Ireland · 1 drug in this class
10. Shiraz University of Medical Sciences · 1 drug in this class